Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX versus ECF for resectable gastric or gastroesophageal junction adenocarcinoma
ACTRN12616001112459Phase 2Recruiting
- Sponsor
- Royal Adelaide Hospital
- Start
- Sep 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, irinotecan, fluorouracil, folinic acid, epirubicin and 1 more in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Royal Adelaide Hospital. Primary endpoint: Progression-free survival. Started Sep 2016; status: recruiting.
02
Drugs
oxaliplatinirinotecanfluorouracilfolinic acidepirubicin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ACTRN12616001112459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001112459.